198 related articles for article (PubMed ID: 32539229)
1. Soluble Vegfr3 gene therapy suppresses multi-organ metastasis in a mouse mammary cancer model.
Shibata MA; Shibata E; Tanaka Y; Shiraoka C; Kondo Y
Cancer Sci; 2020 Aug; 111(8):2837-2849. PubMed ID: 32539229
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
3. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
4. Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer.
Shibata MA; Shibata E; Morimoto J; Harada-Shiba M
Anticancer Res; 2013 Oct; 33(10):4237-47. PubMed ID: 24122987
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.
Shibata MA; Morimoto J; Shibata E; Otsuki Y
Cancer Gene Ther; 2008 Dec; 15(12):776-86. PubMed ID: 18654613
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
9. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
10. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model.
Shibata MA; Ambati J; Shibata E; Albuquerque RJ; Morimoto J; Ito Y; Otsuki Y
BMC Med; 2010 Nov; 8():69. PubMed ID: 21047425
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.
Quagliata L; Klusmeier S; Cremers N; Pytowski B; Harvey A; Pettis RJ; Thiele W; Sleeman JP
Clin Exp Metastasis; 2014 Mar; 31(3):351-65. PubMed ID: 24379135
[TBL] [Abstract][Full Text] [Related]
12. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Guo B; Zhang Y; Luo G; Li L; Zhang J
Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
[TBL] [Abstract][Full Text] [Related]
14. Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
Shibata MA; Ambati J; Shibata E; Yoshidome K; Harada-Shiba M
Med Mol Morphol; 2012 Dec; 45(4):179-84. PubMed ID: 23224595
[TBL] [Abstract][Full Text] [Related]
15. The VEGF-C/VEGFR3 signaling pathway contributes to resolving chronic skin inflammation by activating lymphatic vessel function.
Hagura A; Asai J; Maruyama K; Takenaka H; Kinoshita S; Katoh N
J Dermatol Sci; 2014 Feb; 73(2):135-41. PubMed ID: 24252749
[TBL] [Abstract][Full Text] [Related]
16. Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis.
Larrieu-Lahargue F; Welm AL; Bouchecareilh M; Alitalo K; Li DY; Bikfalvi A; Auguste P
PLoS One; 2012; 7(6):e39540. PubMed ID: 22761819
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
[TBL] [Abstract][Full Text] [Related]
19. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice.
Sun JJ; Jing W; Ni YY; Yuan XJ; Zhou HH; Fan YZ
Asian Pac J Cancer Prev; 2012; 13(6):2823-8. PubMed ID: 22938466
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
